Eliquent Japan, Inc’s Post

#Celltrion secures major supply contracts with #UniHA and #Bretagne, strengthening market leadership in France #Celltrion #Pharmaceuticals #Biosimilars #Healthcare #Innovation #France #UniHA #Bretagne #Remsima #Herzuma #Vegzelma #Omviclone #CTP43 #RASLifeScienceSolutions #MarketIntelligence #MarketResearch #CompetitiveIntelligence #StrategySupport #PortfolioOptimization #MarketExpansion #PartnerIdentification

🚀 Exciting news from Celltrion! 🚀 Celltrion Inc has successfully secured bids to supply three key biopharmaceutical products #Remsima (infliximab), #Herzuma (trastuzumab), and #Vegzelma (bevacizumab) to UniHA, France's largest pharmaceutical procurement group. These biosimilars treat #autoimmunediseases, #breastandgastriccancer, #colorectalcancer, and #nonsmallcelllungcancer. #UniHA controls significant market shares: 30% infliximab, 27% bevacizumab, and 13% trastuzumab. As a result, Celltrion will be the exclusive supplier of these products until June 2027. Additionally, through the #Bretagneprocurementgroup, Celltrion will supply #Herzuma and #Vegzelma until June 2028. Celltrion’s strategy focused on strong relationships with key stakeholders, ESG achievements, and supply stability. The company's #RemsimaSC has also captured a 26% market share, contributing to a combined 76% share for the #Remsima line in France. Looking ahead, Celltrion plans to expand its participation in the French bidding market and strengthen its sales capabilities for newly approved products like #Omviclone (omalizumab) and #CT-P43 (ustekinumab). The company will aggressively participate in upcoming bids and strive for outstanding results to ensure more patients benefit from Celltrion's treatments. #Celltrion #Pharmaceuticals #Biosimilars #Healthcare #Innovation #France #UniHA #Bretagne #Remsima #Herzuma #Vegzelma #Omviclone #CTP43 #Infliximab #Trastuzumab #Bevacizumab #Omalizumab #Ustekinumab #RASLifeScienceSolutions #MarketIntelligence #MarketResearch #CompetitiveIntelligence #StrategySupport #PortfolioOptimization #MarketExpansion #PartnerIdentification For Detailed News: https://lnkd.in/d94c3p4T Follow our page for more industry updates: https://lnkd.in/de5zNWmK

Fierce Pharma's Top 20 Drugs by Worldwide Sales in 2023 🏆 In a fascinating reveal, Fierce Pharma has published its annual list of the pharmaceutical industry's top-performing drugs based on worldwide sales for 2023. This year's rankings highlight the shifting landscape post-pandemic, with a notable decrease in demand for anti-Covid vaccines and a surge in treatments for diabetes and obesity. 👑 Keytruda: Taking the throne as the "king of oncology," Merck's Keytruda leads the pack with over 30 indications for different cancer types and stages. Dominating international sales with a whopping $25 billion, this PD-L1 inhibitor is a cornerstone of Merck's portfolio, accounting for 40% of its total sales. 🥈 Humira: Abbvie's Humira, previously the world's top seller for nine consecutive years, now follows in second place. Though dethroned by Pfizer and BioNTech's Comirnaty in 2021, its legacy continues with robust sales figures. 🥉 Ozempic: Novo Nordisk's Ozempic claims third place. Originally approved for type 2 diabetes treatment, its weight-loss benefits have catapulted it to widespread popularity, boasting sales of $14 billion in 2023. Here's a snapshot of the top industry performers and their 2023 sales: Keytruda (Merck): $25 billion Humira (Abbvie): $14.4 billion Ozempic (Novo Nordisk): $14 billion Eliquis (Bristol Myers Squibb/Pfizer): $12.9 billion Biktarvy (GILEAD): $11.8 billion Dupixent (Regeneron/Sanofi): $11.6 billion Comirnaty (Pfizer/Biontech): $11.2 billion Stelara (Johnson & Johnson): $10.9 billion Opdivo (Bristol Myers Squibb/ONO): $10 billion Darzalex/Darzalex Faspro (Johnson & Johnson): $9.7 billion For a detailed insight into the full list of top 20 drugs, check out the complete report here: https://lnkd.in/ea3RTE7t  Pharmaceuticals #FiercePharma #DrugSales #Keytruda #Oncology #Diabetes #Obesity #HealthcareIndustry

Top Pharmaceutical companies by revenue 9 M* US$Bn updated Nov. 2023 *Individual company Revenue includes sales of all healthcare divisions Worldwide Pharmaceuticals market is projected to reach US$1,115.00bn in 2023 (statista) Global pharmaceutical revenues are forecast to grow at a compounded annual rate of 5.9% to 2028, with global prescription drug sales predicted to be worth $1.6tn in five years (Evaluate World Preview 2023) Biggest growth drivers: developments in obesity, neurological conditions and cancer. Fastest-Growing Therapy Areas to 2028: Immunomodulators (+13.5%), Oncology (+11.4%) and Central Nervous System (+8.6%). Top 3 drugs in 2028: Keytruda (Merck & co): Oncology, Dupixent (Sanofi): Immunomodulator, and Ozempic (Novo Nordisk): Diabetes (Evaluate World Preview 2023) #pharmaceuticals #sales #growth #oncology #immunomodulators #cns #researchanddevelopment #innovation #healthcare #lifesciences

Top Pharmaceutical companies by revenue 9 M* US$Bn updated Nov. 2023 *Individual Company Revenue includes sales of all healthcare divisions Worldwide Pharmaceuticals market is projected to reach US$1,115.00bn in 2023 (statista) Global pharmaceutical revenues are forecast to grow at a compounded annual rate of 5.9% to 2028, with global prescription drug sales predicted to be worth $1.6tn in five years (Evaluate World Preview 2023) Biggest growth drivers: developments in obesity, neurological conditions and cancer. Fastest-Growing Therapy Areas to 2028: Immunomodulators (+13.5%), Oncology (+11.4%) and Central Nervous System (+8.6%). Top 3 drugs in 2028: Keytruda (Merck & co): Oncology, Dupixent (Sanofi): Immunomodulator, and Ozempic (Novo Nordisk): Diabetes (Evaluate World Preview 2023) #pharmaceuticals #sales #growth #oncology #immunomodulators #cns #researchanddevelopment #innovation #healthcare #lifesciences

FDA/CDER Approvals in 2023: A Comprehensive Overview of Novel Drugs The FDA approved 56 innovative drugs in 2023, a 51% increase from the previous year. Pfizer had the highest number of approvals with 6 drugs, while Biogen AstraZeneca , Chiesi Group and UCB also had multiple approvals. The drugs covered various conditions and belonged to different therapeutic classes. #Oncology had the highest number of approvals, followed by neurology and autoimmune disorders. The drugs had different regulatory designations, such as accelerated approval or orphan drug status. For more details please click the link! https://lnkd.in/dChzJjiP #marketaccess #reimbursement #pricing #hta #heor #healtheconomics #medicaldevices #pharmaceutical #fda

Top Pharmaceutical companies by revenue 9 M* US$Bn updated Nov. 2023 *Individual company Revenue includes sales of all healthcare divisions Worldwide Pharmaceuticals market is projected to reach US$1,115.00bn in 2023 (statista) Global pharmaceutical revenues are forecast to grow at a compounded annual rate of 5.9% to 2028, with global prescription drug sales predicted to be worth $1.6tn in five years (Evaluate World Preview 2023) Biggest growth drivers: developments in obesity, neurological conditions and cancer. Fastest-Growing Therapy Areas to 2028: Immunomodulators (+13.5%), Oncology (+11.4%) and Central Nervous System (+8.6%) Top 3 drugs in 2028: Keytruda (Merck & co): Oncology, Dupixent (Sanof): Immunomodulator, and Ozempic (Novo Nordisk): Diabetes (Evaluate World Preview 2023)

Top Pharmaceutical companies by revenue 9 M* US$Bn updated Nov. 2023 *Individual company Revenue includes sales of all healthcare divisions Worldwide Pharmaceuticals market is projected to reach US$1,115.00bn in 2023 (statista) Global pharmaceutical revenues are forecast to grow at a compounded annual rate of 5.9% to 2028, with global prescription drug sales predicted to be worth $1.6tn in five years (Evaluate World Preview 2023) Biggest growth drivers: developments in obesity, neurological conditions and cancer. Fastest-Growing Therapy Areas to 2028: Immunomodulators (+13.5%), Oncology (+11.4%) and Central Nervous System (+8.6%). Top 3 drugs in 2028: Keytruda (Merck & co): Oncology, Dupixent (Sanofi): Immunomodulator, and Ozempic (Novo Nordisk): Diabetes (Evaluate World Preview 2023) #pharmaceuticals #sales #growth #oncology #immunomodulators #cns #researchanddevelopment #innovation #healthcare #lifesciences

Did you know? 80% of the top 10 Pharmaceutical companies are increasing their orphan drug portfolios over the next 3 years towards 35% on average for their respective drug portfolios? With Johnson and Johnson (39%), Vertex (98%), and Astrazeneca (36%) leading the way according to the Evaluate industry report. The ESN Cleer Team 🫀 
#capitalcell #cleerhealth #therapeuticscompany #heartfailure #developing #cardiovasculardisease #heartdisease #hearthealth #heartattacks #heart #stroke #blood #diagnosticstreatments
#personalisedmedicine #BiotechInvestment #PharmaPartnerships #OrphanDrug #CardiomyopathyResearch #HealthInnovation #BioTechDevelopment https://lnkd.in/gJbZjvZa

The risk of market contraction facing the IBD space. For the IBD market to continue to grow, it is critical for biologics entering the market to continue to show substantial efficacy over current biological and small molecules therapies. The increase in inflammatory bowel disease (IBD) biologic treatments has been a major driving force in the growth of this market in recent years. In 2007, AbbVie’s Humira received approval from the #FDA to treat moderate to severe Crohn’s disease. Since that date, the IBD market has seen the entry of seven biologics, with US total sales of these drugs in 2023 reaching approximately $10.2 billion, according to GlobalData market analysis reports of ulcerative colitis and Crohn’s disease. More biologics are anticipated to enter the market in the coming years; however, this segment of the IBD landscape will experience significant events and external forces that could potentially suppress previously observed growth. Barriers to US market growth will primarily result from the loss of patent exclusivity for current biologics and the subsequent entry of biosimilars into these reference therapies. Additionally, pharmaceutical companies must face the growing swell of bipartisan and public support for increased legislation aimed at increasing transparency and reducing the cost of prescription drugs in the US. It should be noted that in this current environment, the stature of pharmaceutical lobbying groups such as the Pharmaceutical Research and Manufacturers of America has diminished, as evidenced by the departure of members AstraZeneca, AbbVie and Teva. The exodus of these companies could also be viewed as an indication of the overall support for such regulations. Alternatively, the factors facing the US market are not expected to have the same impact in the EU and other major markets, such as Canada and Japan, where regulations to keep drug prices low are well-established.